GABA and glutamate systems as therapeutic targets in depression and mood disorders

Bibliography

• SATCHER D: Global health at the crossroads: Surgeon General's report on the 50th World Health Assembly. JAMA (1999) 281(10):942–943.
   PubMedGoogle Scholar
• MURRAY CJ, LOPEZ AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 349(9063):1436–1442.
   PubMed Web of Science ®Google Scholar
• CHISHOLM D, DIEHR P, KNAPP Met al.: Depression status, medical comorbidity and resource costs. Evidence from an international study of major depression in primary care (LIDO). BE J. Psychiatry (2003) 183:121–131.
   Google Scholar
• WYATT RJ, HENTER I: An economic evaluation of manic-depressive illness-1991. Soc. Psychiatry Psychiatr. Epideiniol (1995) 30(5):213–219.
   PubMed Web of Science ®Google Scholar
• MICHELS R, MARZUK PM: Progress in psychiatry (2). N Eng. J. Med. (1993) 329(9):628–638.
   PubMed Web of Science ®Google Scholar
• CHARNEY DS: Monoamine dysfunction and the pathophysiology and treatment of depression. J. Clin. Psychiatry (1998) 59 (Suppl. 14):11–14.
   Google Scholar
• KORNSTEIN SG, SCHNEIDER RK: Clinical features of treatment-resistant depression. J. Clin. Psychiatry (2001) 62\(Suppl. 16):18–25.
   Google Scholar
• SACHS GS: Unmet clinical needs in bipolar disorder. J. Clin. Psychopharinacol (2003) 23(3 Suppl. 1):S2–S8.
   Google Scholar
• KRYSTAL JH, SANACORA G, BLUMBERG H et al: Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry (2002) 7\(Suppl. 1):571–580.
   Google Scholar
• EMRICH HM, VON ZERSSEN D, KISSLING W, MOLLER HJ, WINDORFER A: Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch. Psychiatr. Nervenkr (1980) 229(1):1–16.
   PubMedGoogle Scholar
• PETTY F: GABA and mood disorders: a brief review and hypothesis. J. Affect. Disord. (1995) 34(4):275–281.
   PubMedGoogle Scholar
• SHIAH IS, YATHAM LN: GABA function in mood disorders: an update and critical review. Life Li. (1998) 63(15):1289–303.
   Google Scholar
• SANACORA G, MASON GE KRYSTAL JH: Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Grit. Rev Neurobiol (2000) 14(1):23–45.
   PubMedGoogle Scholar
• TUNNICLIFF GE, MALATYNSKA E: Central GABAergic systems and depressive illness. Neurochein. Res. (2003) 28(6):965–976.
   PubMedGoogle Scholar
• BRAMBILLA P, PEREZ J, BARALE F, SCHETTINI G, SOARES JC: GABAergic dysfunction in mood disorders. Mol Psychiatry (2003) 8(8):721–737.
   PubMed Web of Science ®Google Scholar
• PAREDES RG, AGMO A: GABA and behavior: the role of receptor subtypes. Neurosci. Biobehav. Rev (1992) 16(2):145–170.
   PubMedGoogle Scholar
• MARTIN DL, RIMVALL K: Regulation of gamma-aminobutyric acid synthesis in the brain. Neurochein. (1993) 60(2):395–407.
   PubMed Web of Science ®Google Scholar
• ERECINSKA M, SILVER IA: Metabolism and role of glutamate in mammalian brain. Prog. Neurobiol (1990) 35(4):245–296.
   PubMed Web of Science ®Google Scholar
• NICHOLLS DG: Release of glutamate, aspartate, and gamma-aminobutyric acid from isolated nerve terminals. J. Neurochein. (1989) 52(2):331–341.
   PubMed Web of Science ®Google Scholar
• LUDDENS H, KORPI ER: Biological function of GABAA/benzodiazepine receptor heterogeneity. J. Psychiam Res. (1995) 29(2):77–94.
   PubMedGoogle Scholar
• PAUL S: GABA and glycine. In: Psychopharmacology: The fourth generation of progress. Bloom FE, Kupfer DJ (Eds), Raven Press, New York (1995):87–94.
   Google Scholar
• PAUL SM, PURDY RH: Neuroactive steroids. FASEB J. (1992) 6(6):2311–2322.
   PubMed Web of Science ®Google Scholar
• RUPPRECHT R: The neuropsychopharmacological potential of neuroactive steroids. Psychiatr. Res. (1997) 31(3):297–314.
   Google Scholar
• KAUPMANN K, HUGGEL K, HEID J et al: Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature (1997) 386(6622):239–246.
   PubMed Web of Science ®Google Scholar
• DAVIES CH, COLLINGRIDGE GL: Regulation of EPSPs by the synaptic activation of GABAB autoreceptors in rat hippocampus. Physiol (1996) 496(Pt 2):451–470.
   Google Scholar
• SCHULTZ LM, CLARK GA: GABA-induced synaptic facilitation at type B to A photoreceptor connections in Hermissenda. Brain Res. Bulletin (1997) 42(5):377–383.
   PubMedGoogle Scholar
• BIGGO G, CONCAS A, SERRA M et al:Stress and beta-carbolines decrease the density of low affinity GABA binding sites: an effect reversed by diazepam. Brain Res. (1984) 305:13–18.
   PubMedGoogle Scholar
• CONCAS A, SERRA M, ATSOGGIU T, BIGGO G: Foot-shock stress and anxiogenic beta-carbolines increase t-[35S]butylbicyclophosphorothionate binding in the rat cerebral cortex, an effect opposite to anxiolytics and gamma-aminobutyric acid mimetics. Neurochein. (1988) 51(6):1868–1876.
   PubMedGoogle Scholar
• WEIZMAN R, WEIZMAN A, KOOK KA et al: Repeated swim stress alters brain benzodiazepine receptors measured in vivo. Pharmacol Exp. Ther. (1989) 249(3):701–707.
   PubMedGoogle Scholar
• SERRA M, SANNA E, CONCAS A, FODDI C, BIGGIO G: Foot-shock stress enhances the increase of [35S]TBPS binding in the rat cerebral cortex and the convulsions induced by isoniazid. Neurochein. Res. (1991) 16(1):17–22.
   PubMedGoogle Scholar
• SANNA E, CUCCHEDDU T, SERRA M, CONCAS A, BIGGIO G: Carbon dioxide
   Google Scholar
• •• inhalation reduces the function of GABAA receptors in the rat brain. Eur. Pharmacol (1992) 216(3):457–458.
   Google Scholar
• BORSINI F, MANCINELLI A, D'ARANNO V, EVANGELISTA S, MELT A: On the role of endogenous GABA in the forced swimming test in rats. Pharmacol. Biochem. Behav. (1988) 29(2):275–279.
   PubMedGoogle Scholar
• ACOSTA GB, OTERO LOSADA ME, RUBIO MC: Area-dependent changes in GABAergic function after acute and chronic cold stress. Neurawi. Lett. (1993) 154(1-2):175–178.
   PubMedGoogle Scholar
• ACOSTA GB, RUBIO MC: GABAA receptors mediate the changes produced by stress on GABA function and locomotor activity. NeurawL Lett. (1994) 176(1):29–31.
   PubMedGoogle Scholar
• INSEL TR: Decreased in vivo binding to brain benzodiazepine receptors during social isolation. Psychopharmacology (1989) 97(2):142–144.
   PubMedGoogle Scholar
• CALDJI C, DIORIO J, MEANEY MJ: Variations in maternal care in infancy regulate the development of stress reactivity. Biol. Psychiatry (2000) 48(12):1164–1174.
   PubMedGoogle Scholar
• CALDJI C, DIORIO J, MEANEY MJ: Variations in maternal care alter GABA(A) receptor subunit expression in brain regions associated with fear. Neuropsychopharmacology (2003) 28(11):1950–1959.
   PubMedGoogle Scholar
• SHERMAN AD, PETTY F: Neurochemical basis of the action of antidepressants on learned helplessness. Behav. Neural Biol. (1980) 30(2):119–134.
   PubMedGoogle Scholar
• BORSINI F, EVANGELISTA S, MELT A: Effect of GABAergic drugs in the behavioral 'despair' test in rats. Eur. Pharmacol. (1986) 121(2):265–268.
   PubMedGoogle Scholar
• LLOYD KG, ZIVKOVIC B, SCATTON B, MORSELLI PL, BARTHOLINI G: The gabaergic hypothesis of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry (1989) 13(3-4):341–351.
   PubMed Web of Science ®Google Scholar
• PETTY F, STEINBERG J, KRAMER GL, FULTON M, MOELLER FG: Desipramine does not alter plasma GABA in patients with major depression. J. Affect. Disord. (1993) 29(1):53–56.
   PubMedGoogle Scholar
• PETTY F: Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease? Clin. Chem. (1994) 40(2):296–302.
   Google Scholar
• SANACORA G, MASON GF, ROTHMAN DL et al.: Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry (1999) 56(11):1043–1047.
   PubMed Web of Science ®Google Scholar
• SANACORA G, GUEORGUIEVA R, EPPERSON CN et al.: Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry (2004) 61(7):705–713.
   PubMed Web of Science ®Google Scholar
• SANACORA G, MASON GF, ROTHMAN DL et al.: Increased cortical GABA concentrations in depressed patients receiving ECT. Am. J. Psychiatry (2003) 160(3):577–579.
   PubMed Web of Science ®Google Scholar
• SANACORA G, MASON GF, ROTHMAN DL, KRYSTAL JH: Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am. J. Psychiatry (2002) 159(4):663–665.
   PubMed Web of Science ®Google Scholar
• RAJIKOWSKA G, O'DWYER G, SHAO Q, STOCKMEIER CA, MIGUEL-HIDALGO JJ: Calbindin-immunoreactive non-pyramidal neurons are reduced in the dorsolateral prefrontal cortex in major depression and schizophrenia. Society for Neuroscience 2002, Washington DC.
   Google Scholar
• PETTY F, FULTON M, KRAMER GL et al.: Evidence for the segregation of a major gene for human plasma GABA levels. Mol. Psychiatry (1999) 4(6):587–589.
   PubMedGoogle Scholar
• LAPPALAINEN J, SANACORA G, KRANZLER HR et al: Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. Am. Med. Genet. (2004) 124B (1) :81–86.
   PubMedGoogle Scholar
• HORIUCHI Y, NAKAYAMA J, ISHIGURO H et al.: Possible association between a haplotype of the GABA-A receptor alpha 1 subunit gene (GABRA1) and mood disorders. Biol. Psychiatry (2004) 55(1):40–45.
   PubMed Web of Science ®Google Scholar
• SEN S, VILLAFUERTE S, NESSE R et al.: Serotonin transporter and GABAA alpha 6 receptor variants are associated with neuroticism. Biol. Psychiatry (2004) 55(3):244–249.
   PubMedGoogle Scholar
• BARTHOLINI G, LLOYD KG, MORSELLI PL (Eds): GABA and mood disorders: experimental and clinical research LEES. monograph series (Vol. 4). Raven Press, New York (1986).
   Google Scholar
• SCHATZBERG AF, COLE JO: Benzodiazepines in depressive disorders. Arch. Gen. Psychiatry (1978) 35:1359–1365.
   PubMed Web of Science ®Google Scholar
• TILLER JW, SCHWEITZER I, MAGUIRE KP, DAVIS B: Is diazepam an antidepressant? Br. Psychiatry (1989) 155:483–489.
   Google Scholar
• PETTY F, TRIVEDI MH, FULTON M, RUSH AJ: Benzodiazepines as antidepressants: does GABA play a role in depression? Biol. Psychiatry (1995) 38(9):578–591.
   Google Scholar
• FURUKAWA TA, STREINER DL, YOUNG LT: Antidepressant and benzodiazepines for major depression. In: Cochrane Review The Cochrane Library, John Wiley & Sons, Ltd,Chichester, UK (2004):1.
   Google Scholar
• •This paper demonstrates the clinical benefits of benzodiazepine addition to other antidepressant medications in the treatment of major depression.
   Google Scholar
• ROMEO E, STROHLE A, SPALLETTA G et al.: Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry (1998) 155(7):910–913.
   PubMed Web of Science ®Google Scholar
• ••This manuscript describes a studydemonstrating that clinically effective treatment with antidepressants alters the concentrations of neuroactive steroids in patients suffering from a major depressive episode.
   Google Scholar
• UZUNOV DP, COOPER TB, COSTA E, GUIDOTTI: Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Nat. Acad. Sci. USA (1996) 93(22):12599–12604.
   PubMedGoogle Scholar
• ROSENTHAL M: Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. Psychiatry (2003) 64(10):1245–1249.
   Google Scholar
• CARPENTER LL, TYRKA AR, SCHECTER J, HAGGARTY R, PRICE, LH: Tiagabine for major depression with anxiety. Biol. Psychiatry (2003) 53:38S.
   Google Scholar
• SUPPES T, CHRISHOLM KA, DHAVALE D et al: Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord. (2002) 4(5):283–289.
   PubMedGoogle Scholar
• LOSCHER W: Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem. Res. (1993) 18(4):485–502.
   PubMedGoogle Scholar
• BOWDEN CL, BRUGGER AM, SWANN AC et al.: Efficacy of divalproex versus lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA (1994) 271(12):918–924.
   PubMed Web of Science ®Google Scholar
• DAVIS LL, KABEL D, PATEL D et al: Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull. (1996) 32(4):647–652.
   PubMedGoogle Scholar
• PETTY F, RUSH AJ, DAVIS JM et al: Plasma GABA predicts acute response to divalproex in mania. Biol. Psychiatry (1996) 39(4):278–284.
   PubMedGoogle Scholar
• MOTOHASHI N: GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Prog. Neuropsychophannacol Biol.Psychiatry (1992) 16(4):571–579.
   PubMedGoogle Scholar
• OLPE HR, STEINMANN MW, POZZA MF, BRUGGER F, SCHMUTZ M: Valproate enhances GABA-A mediated inhibition of locus coeruleus neurones in vitro. Naunyn Schnnedebergs Arch. Pharmacol (1988) 338(6):655–657.
   PubMedGoogle Scholar
• BROWN ES, SUPPES T, McELROY S et al.: A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. In: Society of Biology and Psychiatry Washington DC (1999).
   Google Scholar
• POST RM, LEVERICH GS, DENICOFF KD et al: Alternative approaches to refractory depression in bipolar illness. Depress. Anxiety (1997) 5(4):175–189.
   PubMedGoogle Scholar
• PETROFF OA, ROTHMAN DL, BEHAR KL, COLLINS TL, MATTSON RH: Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology (1996) 47(6):1567–1571.
   PubMedGoogle Scholar
• GOLDLUST A, SU TZ, WELTY DF, TAYLOR CP, OXENDER DL: Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res. (1995) 22(1):1–11.
   PubMedGoogle Scholar
• KELLY KM: Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology (1998) 38(3):139–144.
   PubMedGoogle Scholar
• HONMOU 0, OYELESE AA, KOCSIS JD: The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res. (1995) 692(1-2):273–277.
   PubMedGoogle Scholar
• CARTA MG, HARDOY MC, HARDOY MJ, GRUNZE H, CARPINELLO B: The clinical use of gabapentin in bipolar spectrum disorders. J. Affect. Disord. (2003) 75(1):83–91.
   PubMed Web of Science ®Google Scholar
• PANDE AC, CROCKATT JG, JANNEY CA, WERTH JL, TSAROUCHA G: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. (2000) 2(3 Pt 2):249–255.
   Google Scholar
• FRYE MA, KETTER TA, KIMBRELL TA et al.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol (2000) 20(6):607–614.
   PubMed Web of Science ®Google Scholar
• FELTNER DE, CROCKATT JG, DUBOVSKY SJ et al: A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol (2003) 23(3):240–249.
   PubMed Web of Science ®Google Scholar
• LAURIA-HORNER BA, POHL RB: Pregabalin: a new anxiolytic. Expert Opin. Investig. Drugs (2003) 12(4):663–672.
   PubMed Web of Science ®Google Scholar
• ERRANTE LD, PETROFF OA: Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure (2003) 12(5):300–306.
   PubMedGoogle Scholar
• WHITE HS, BROWN SD, WOODHEAD JH, SKEEN GA, WOLF HH: Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. (1997) 28(3):167–179.
   PubMed Web of Science ®Google Scholar
• SCHNEIDERMAN JH: Topiramate: pharmacokinetics and pharmacodynamics. Can. J. Neurol Sci. (1998) 25(3):53–55.
   Google Scholar
• KUZNIECKY RI, HETHERINGTON HP, HO S: Topiramate increases cerebral GABA in healthy humans. Neurology (1998) 51:627–629.
   PubMedGoogle Scholar
• PETROFF OA, HYDER F, MATTSON RH, ROTHMAN DL: Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology (1999) 52(3):473–478.
   PubMedGoogle Scholar
• SUPPES T: Review of the use of topiramatefor treatment of bipolar disorders. J. Clin. Psychopharmacol (2002) 22(6):599–609.
   PubMed Web of Science ®Google Scholar
• CHENGAPPA KN, RATHORE D, LEVINE J et al.: Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord. (1999) 1(1):42–53.
   PubMedGoogle Scholar
• GRUNZE HC, NORMANN C, LANGOSCH J et al.: Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J. Clin. Psychiatry (2001) 62(6):464–468.
   PubMedGoogle Scholar
• MARCOTTE D: Use of topiramate, a new anti-epileptic as a mood stabilizer. J. Affect. Disord. (1998) 50(2-3):245–251.
   PubMed Web of Science ®Google Scholar
• VIETA E, SANCHEZ-MORENO J, GOIKOLEA et al: Adjunctive topiramate in bipolar II disorder. World J. Biol. Psychiatry (2003) 4(4):172–176.
   PubMed Web of Science ®Google Scholar
• CALABRESE JR, SHELTON MD, BOWDEN CL et al.: Bipolar rapid cycling: focus on depression as its hallmark.j Clin. Psychiatry (2001) 62\(Suppl. 14):34–41.
   Google Scholar
• BERRETTINI WH, NURNBERGER JI Jr, HARTE TA et al: Reduced plasma and CSF gamma-aminobutyric acid in affective illness: effect of lithium carbonate. Biol. Psychiatry (1983) 18(2):185–194.
   PubMedGoogle Scholar
• MOTOHASHI N, IKAWA K, KARIYA T: GABAB receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders? Eur. Phannacol (1989) 166(0:95–99.
   Google Scholar
• SNYDER SH, FERRIS CD: Novel neurotransmitters and their neuropsychiatric relevance. Am .j Psychiatry (2000) 157(11):1738–1751.
   PubMed Web of Science ®Google Scholar
• OBRENOVITCH TP, URENAK J, ZILKHA E, JAY TM.: Excitotoxicity in neurological disorders - the glutamate paradox. Int. J. Dev. Neurosci. (2000) 18(2–3):281–287.
   Google Scholar
• OLNEY JW: Role of excitotoxins in developmental neuropathology. APMIS Suppl. (1993) 40:103–112.
   PubMedGoogle Scholar
• SANACORA G, ROTHMAN DL, MASON G, KRYSTAL JH: Clinical studies implementing glutamate neurotransmission in mood disorders. Ann. NY Acad. Sci. (2003) 1003:292–308.
   PubMed Web of Science ®Google Scholar
• GREENAMYRE JT: Glutamatergic influences on the basal ganglia. Clin. Neurophannacol (2001) 24(2):65–70.
   PubMedGoogle Scholar
• COOPER JR, BLOOM FE, ROTH RH: In: The Biochemical Bash of Neuropharmacology. Oxford University Press, Inc., New York (2003).
   Google Scholar
• BRIDGES RJ: The ins and outs of glutamate transporter pharmacology Tocris Rev. (2001) 17:1–5.
   Google Scholar
• DANBOLT NC: The high affinity uptake system for excitatory amino acids in the brain. Frog. Neurobiol (1994) 44(4):377–396.
   Google Scholar
• VANHOUTTE P, BADING H: Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr. Opin. Neurobiol (2003) 13(3):366–371.
   PubMedGoogle Scholar
• ••An examination of differences in biologicalresponse to NMDA receptors based on their location (synaptic versus extrasynaptic) and subsequent impact on neurotropic factors and receptor trafficking.
   Google Scholar
• NIKAM SS, MELTZER LT: NR2B selective NMDA receptor antagonists. Current Pharmaceutical Design (2002) 8(10):845–855.
   PubMed Web of Science ®Google Scholar
• •This paper examines the NR2B class of excitatory amino acid receptor antagonists. Previous research on this class has shown efficacy in neuroprotection and anti-Parkinson animal models.
   Google Scholar
• LINDEN AM, GREENE SJ, BERGERON M, SCHOEPP DD: Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology (2004) 29(3):502–513.
   PubMedGoogle Scholar
• SWANSON CJ, SCHOEPP DD: A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mG1u2/3 receptor agonists. Ann. NY Acad. Sci. (2003) 1003:309–317.
   PubMedGoogle Scholar
• WINTER JC, ECKLER JR, RABIN RA: Serotonergic/glutamatergic interactions: the effects of mG1u2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology (2004) 172(2):233–240.
   PubMedGoogle Scholar
• RIEGEL AC, ALI SF, FRENCH ED: Toluene-induced locomotor activity is blocked by 6-hydroxydopamine lesions of the nucleus accumbens and the mGluR2/3 agonist LY379268. Neuropsychopharmacology (2003) 28(8):1440–1447.
   PubMed Web of Science ®Google Scholar
• HIGGINS GA, BALLARD TM, KEW JN et al: Pharmacological manipulation of mG1u2 receptors influences cognitive performance in the rodent. Neuropharmacology (2004) 46(7):907–917.
   PubMed Web of Science ®Google Scholar
• CHAVEZ-NORIEGA LE, SCHAFFHAUSER H, CAMPBELL UC: Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Curr. Drug Targets CNS Neurol. Disord. (2002) 1(3):261–281.
   PubMedGoogle Scholar
• HENRICH-NOACK P, HATTON CD, REYMANN KG: The mGlu receptor ligand (S)-4C3HPG protects neurons after global ischaemia in gerbils. Neuroreport (1998) 9 (6) :985–988.
   PubMedGoogle Scholar
• MICHELI F, FABIO RD, CAVANNI P et al.: Synthesis and pharmacological characterisation of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists. Bioorg. Med. Chem. (2003) 11(2):171–183.
   PubMedGoogle Scholar
• SOTGIU ML, BELLOMI P, BIELLA GE: The mGluR5 selective antagonist 6-methyl-2-(phenylethyny1)-pyridine reduces the spinal neuron pain-related activity in mononeuropathic rats. Neurasci. Lett. (2003) 342(1-2):85–88.
   PubMedGoogle Scholar
• BATTAGLIA G, BRUNO V, PISANI A et al: Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission. Mol Cell. Neurosci. (2001) 17(6):1071–1083.
   PubMedGoogle Scholar
• TATARCZYNSKA E, KLODZINSKA A, CHOJNACKA-WOJCIK E et al.: Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mG1u5 receptor antagonist. BE J Pharmacol (2001) 132(7):1423–1430.
   PubMed Web of Science ®Google Scholar
• BATTAGLIA G, BUSCETI CL, MOLINARO G et al: Endogenous activation of mG1u5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine in mice. J NeurascL (2004) 24(4):828–835.
   PubMedGoogle Scholar
• LI X, TIZZANO JP, GRIFFEY K et al.: Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology (2001) 40 (8) : 1028–33.
   PubMedGoogle Scholar
• LYNCH G: AMPA receptor modulators as cognitive enhancers. Curr. Opin. Pharmacol (2004) 4(1):4–11.
   PubMedGoogle Scholar
• LERMA J: [Synaptic physiology of the kainate receptors and its influence in epileptogenesis]. Neurologia (2004) 19(3):106–116. [Spanish].
   Google Scholar
• RUSCHEWEYH R, SANDKUHLER J: Role of kainate receptors in nociception. Brain Res. Brain Res. Rev (2002) 40(1-3):215–222.
   PubMedGoogle Scholar
• SHIGERI Y, SHIMAMOTO K: [Pharmacology of excitatory amino acid transporters (EAATs and VGLUTs)]. Nippon Yakurigaku Zasshi - Folia Pharmacologica Japonica (2003) 122(3):253–264. [Japanese].
   Google Scholar
• HAYASE T, YAMAMOTO Y, YAMAMOTO K: Brain excitatory amino acid transporters (EAATs) and treatment of methamphetamine toxicity. Nihon Arukoru Yakubutsu Igakkai Zasshi (2003) 38(6):498–511.
   PubMedGoogle Scholar
• SAPOLSKY RM: Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry (2000) 57(10):925–935.
   PubMed Web of Science ®Google Scholar
• MOGHADDAM B, BOLINAO ML, STEIN-BEHRENS B, SAPOLSKY R: Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Broth Res. (1994) 655(1-2):251–254.
   PubMedGoogle Scholar
• MOGHADDAM B: Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. .1 Neurochem. (1993) 60 (5) :1650–1657.
   Google Scholar
• LOWY MT, WITTENBERG L, YAMAMOTO BK: Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem. (1995) 65(1):268–274.
   PubMedGoogle Scholar
• BAGLEY J, MOGHADDAM B: Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience (1997) 77(1):65–73.
   PubMed Web of Science ®Google Scholar
• NOWAK G, ORDWAY GA, PAUL IA: Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. (1995) 675(1-2):157–164.
   PubMedGoogle Scholar
• NOWAK G, OSSOWSKA G, JOPEK R, PAPP M: Strychnine-insensitive glycine/NMDA sites are altered in two stress models of depression. Poi J. Pharinacol (1998) 50(4-5):365–369.
   Google Scholar
• FITZGERALD LR, VAIDYA VA, TERWILLIGER RZ, DUMAN RS: Electroconvulsive seizure increases the expression of CREM (cyclic AMP response element modulator) and ICER (inducible cyclic AMP early repressor) in rat brain. Neurochein. (1996) 66(1):429–432.
   PubMedGoogle Scholar
• BARTANUSZ V, AUBRY JM, PAGLIUSI S et al.: Stress-induced changes in messenger RNA levels of N-methyl-D-aspartate and AMPA receptor subunits in selected regions of the rat hippocampus and hypothalamus. Neuroscience (1995) 66(2):247–252.
   PubMedGoogle Scholar
• ROCERI M, HENDRIKS W, RACAGNI G, ELLENBROEK BA, RIVA MA: Early maternal deprivation reduces the expression of BDNF and NMDA receptor subunits in rat hippocampus. Psychiatry (2002) 7(6):609–616.
   Google Scholar
• ABRAHAM I, JUHASZ G, KEKESI KA, KOVACS KJ: Corticosterone peak is responsible for stress-induced elevation of glutamate in the hippocampus. Stress (1998) 2(3):171–181.
   PubMedGoogle Scholar
• LEE PR, BRADY D, KOENIG JI: Corticosterone alters N-methyl-D-aspartate receptor subunit mRNA expression before puberty. Brain Res. Mol. Brain Res. (2003) 115(1):55–62.
   PubMedGoogle Scholar
• BREMNER JD, NARAYAN M, ANDERSON ER et al.: Hippocampal volume reduction in major depression. Ain. J. Psychiatry (2000) 157(1):115–118.
   PubMed Web of Science ®Google Scholar
• SHELINE YI, WANG PW, GADO MH, CSERNANSKY JG, VANNIER MW: Hippocampal atrophy in recurrent major depression. Proc. Nati Acad. Sci. USA (1996) 93(9):3908–3913.
   PubMed Web of Science ®Google Scholar
• SHELINE YI: Hippocampal atrophy in major depression: a result of depression-induced neurotoxicity? Mol. Psychiatry (1996) 1(4):298–299.
   Google Scholar
• RAJKOWSKA G, MIGUEL-HIDALGO JJ, WEI J et al: Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry (1999) 45(9):1085–1098.
   PubMed Web of Science ®Google Scholar
• ONGUR D, DREVETS WC, PRICE JL: Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl Acad. Sci. USA (1998) 95(22):13290–13295.
   PubMed Web of Science ®Google Scholar
• COTTER D, MACKAY D, CHANA G et al.: Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb. Cortex (2002) 12(4):386–394.
   PubMed Web of Science ®Google Scholar
• HAMIDI M, DREVETS WC, PRICE JL: Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol. Psychiatry (2004) 55(6):563–569.
   PubMedGoogle Scholar
• TANAKA J, ICHIKAWA R, WATANABE M, TANAKA K, INOUE Y: Extra-junctional localization of glutamate transporter EAAT4 at excitatory Purkinje cell synapses. Neuroreport (1997) 8(10:2461–2464.
   PubMedGoogle Scholar
• MATHEW SJ, SHUNGU DC, MAO X et al.: A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biol. Psychiatry (2003) 54(7):727–735.
   PubMedGoogle Scholar
• ZIEGLER DR, HERMAN JP: Local integration of glutamate signaling in the hypothalamic paraventricular region: regulation of glucocorticoid stress responses. Endocrinology (2000) 141(12):4801–4804.
   PubMed Web of Science ®Google Scholar
• CRATTY MS, BIRKLE DL: N-methyl-D-aspartate (NMDA)-mediated corticotropin-releasing factor (CRF) release in cultured rat amygdala neurons. Peptides (1999) 20(1):93–100.
   PubMedGoogle Scholar
• FELDMAN S, WEIDENFELD J: Hypothalamic mechanisms mediating glutamate effects on the hypothalamo-pituitary-adrenocortical axis. J. Neural Transin. (1997) 104(6-7):633–642.
   PubMed Web of Science ®Google Scholar
• KIM JS, SCHMID-BURGK W, CLAUS D, KORNHUBER HH: Increased serum glutamate in depressed patients. Arch. Psychiatr: Nervenkr. (1982) 232(4):299–304.
   PubMedGoogle Scholar
• ALTAMURA CA, MAURI MC, FERRARA A et al: Plasma and platelet excitatory amino acids in psychiatric disorders. Ain. J. Psychiatry (1993) 150(10:1731–1733.
   PubMedGoogle Scholar
• MAURI MC, FERRARA A, BOSCATI L et al.: Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology (1998) 37(3):124–129.
   PubMed Web of Science ®Google Scholar
• ALTAMURA C, MAES M, DAI J, MELTZER HY: Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur. Neuropsychophannacol (1995) 5(Suppl.):71–75.
   Google Scholar
• MAES M, VERKERK R, VANDOOLAEGHE E, LIN A, SCHARPE S et al.: Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr. Scand. (1998) 97(4):302–308.
   PubMed Web of Science ®Google Scholar
• FRANCIS PT, POYNTON A, LOWE SL et al: Brain amino acid concentrations and Ca2+-dependent release in intractable depression assessed antemortem. Brain Res. (1989) 494(2):315–324.
   PubMedGoogle Scholar
• AUER DP, PUTZ B, KRAFT E et al.: Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol. Psychiatry (2000) 47(4):305–313.
   PubMed Web of Science ®Google Scholar
• MICHAEL N, ERFURTH A, PECUCH P et al: Clinical response to electroconvulsive (ECT) restores reduced glutamate/glutamine levels in the left anterior cingulum of severely depressed patients. World Congress of Biol. Psychiatry 2001, Berlin, Germany
   Google Scholar
• MAHESHWARI SR, FATTERPEKAR GM, CASTILLO M, MUKHERJI SK: Proton MR spectroscopy of the brain. Semi]. Ultrasound CT MR (2000) 21(6):434–451.
   PubMed Web of Science ®Google Scholar
• SANACORA G, GUEORGUIEVA R, EPPERSON CN et al.: Subtype-specific alterations of GABA and glutamate in major depression. Arch. Cen. Psychiatry (2005) In Press.
   Google Scholar
• HOLEMANS S, DE PAERMENTIER F, HORTON RW et al: NMDA glutamatergic receptors labelled with [3H]MK-801 in brain samples from drug-free depressed suicides. Brain Res (1993) 616:138–143.
   PubMed Web of Science ®Google Scholar
• NOWAK G, ORDWAY GA, PAUL IA: Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. (1995) 675(1-2):157–164.
   PubMedGoogle Scholar
• KAMPHUIS PJ, GARDONI F, KAMAL A et al.: Long-lasting effects of neonatal dexamethasone treatment on spatial learning and hippocampal synaptic plasticity: involvement of the NMDA receptor complex. FASEB J. (2003) 17(8):911–913.
   PubMed Web of Science ®Google Scholar
• MEADOR-WOODRUFF JH, HOGG AJ Jr, SMITH RE: Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res. Bulletin (2001) 55(5):631–640.
   PubMedGoogle Scholar
• REYNOLDS IJ, MILLER RJ: Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. BE J. Pharmacol. (1988) 95(1):95–102.
   PubMedGoogle Scholar
• NOWAK G, TRULLAS R, LAYER RT, SKOLNICK P, PAUL IA: Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. Pharmacol. Exp. The]: (1993) 265(3):1380–1386.
   PubMedGoogle Scholar
• SKOLNICK P, LAYER RT, POPIK P et al.: Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharinacopsychiatry (1996) 29(1):23–26.
   PubMed Web of Science ®Google Scholar
• PAUL IA, LAYER RT, SKOLNICK P, NOWAK G: Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur. Pharmacol. (1993) 247(3):305–311.
   PubMedGoogle Scholar
• BOYER PA, SKOLNICK P, FOSSOM LH: Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. ./. Mol Neurosci. (1998) 10(3):219–233.
   PubMedGoogle Scholar
• WATKINS CJ, PEI Q, NEWBERRY NR: Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b. Brain Res. Molecular Brain Res. (1998) 61(1-2):108–113.
   PubMedGoogle Scholar
• HASHIMOTO R, HOUGH C, NAKAZAWA T, YAMAMOTO T, CHUANG DM: Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. Neurochein. (2002) 80(4):589–597.
   PubMed Web of Science ®Google Scholar
• PADOVAN CM, GUIMARAES FS: Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats. Pharmacol. Biochein. Behav. (2004) 77(1):15–19.
   PubMedGoogle Scholar
• MAJ J, ROGOZ Z, SKUZA G, SOWINSKA H: Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur. Neuropsychopharinacol. (1992) 2(1):37–41.
   PubMedGoogle Scholar
• PAD OVAN CM, DEL BEL EA, GUIMARAES FS: Behavioral effects in the elevated plus maze of an NMDA antagonist injected into the dorsal hippocampus: influence of restraint stress. Pharmacol. Biochein. Behav. (2000) 67(2):325–330.
   PubMedGoogle Scholar
• POPIK P, WROBEL M, NOWAK G: Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence. Neuropharmacology (2000) 39(12):2278–2287.
   PubMedGoogle Scholar
• OSSOWSKA G, KLENK-MAJEWSKA B, SZYMCZYK G: The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats. ./. Physiol. Pharmacol. (1997) 48(1):127–135.
   PubMedGoogle Scholar
• MORYL E, DANYSZ W, QUACK G: Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol. Toxicol. (1993) 72(6):394–397.
   PubMedGoogle Scholar
• PAPP M, MORYL E: Rewarding properties of non-competitive and competitive NMDA antagonists as measured by place preference conditioning in rats. Poll Pharmacol. (1994) 46(1-2):79–81.
   PubMedGoogle Scholar
• ROGOZ Z, SKUZA G, MAJ J, DANYSZ W: Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology (2002) 42(8):1024–1030.
   PubMedGoogle Scholar
• PAUL IA, TRULLAS R, SKOLNICK P, NOWAK G: Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology (1992) 106(2):285–287.
   PubMedGoogle Scholar
• NACHER J, ROSELL DR, ALONSO-LLOSA G, McEWAN BS: NMDA receptor antagonist treatment induces a long-lasting increase in the number of proliferating cells, PSA-NCAM-immunoreactive granule neurons and radial glia in the adult rat dentate gyrus. Eur. Neurosci. (2001) 13(3):512–520.
   PubMedGoogle Scholar
• NACHER J, ALONSO-LLOSA G, ROSELL DR, McEWAN BS: NMDA receptor antagonist treatment increases the production of new neurons in the aged rat hippocampus. Neurobiol. Aging (2003) 24(2):273–284.
   PubMedGoogle Scholar
• YILMAZ A, SCHULZ D, AKSOY A, CANBEYLI R: Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol. Biochein. Behav. (2002) 71(1-2):341–344.
   PubMed Web of Science ®Google Scholar
• CRANE GE: Cycloserine as an antidepressant agent. Am. I. Psychiatry (1959) 115:1025–1026.
   PubMed Web of Science ®Google Scholar
• CRANE GE: The psychotropic effects of cycloserine: a new use of an antibiotic. Comprehensive Psychaitry (1961) 2:51–59.
   Google Scholar
• MONAHAN JB, HANDELMANN GE, HOOD WF, CORDI AA: D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol. Biochem. Behav. (1989) 34(3):649–653.
   PubMed Web of Science ®Google Scholar
• HOOD WE COMPTON RP, MONAHAN JB: D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci. Lett. (1989) 98(1):91–95.
   PubMedGoogle Scholar
• EMMETT MR, MICK SJ, CLER JA et al.: Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology (1991) 30(10:1167–1171.
   PubMedGoogle Scholar
• HENDERSON G, JOHNSON JW, ASCHER P: Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-D-aspartate receptor. J. Physiol. (1990) 430:189–212.
   PubMed Web of Science ®Google Scholar
• PARKES JD, CALVER DM, ZILKHA KJ, KNILL-JONES RP: Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet (1970) 1(7641):259–262.
   PubMedGoogle Scholar
• MINDHAM RH, MARSDEN CD, PARKES JD: Psychiatric symptoms during 1-dopa therapy for Parkinson's disease and their relationship to physical disability. Psycho]. Med. (1976) 6(1):23–33.
   PubMedGoogle Scholar
• VALES, ESPEJEL MA, DOMINGUEZ JC: Amantadine in depression. Lancet (1971) 2(7721):437.
   Google Scholar
• DIETRICH DE, KLEINSCHMIDT A, HAUSER U et al: Word recognition memory before and after successful treatment of depression. Pharmacopsychiatry (2000) 33(6):221–228.
   PubMedGoogle Scholar
• FERSZT R, KUHL KP, BODE L et al: Amantadine revisited: an open trial of amantadinesulfatetreatment in chronically depressed patients with Borna disease virus infection.Pharmacopsychiatry (1999) 32(4):142–147.
   PubMedGoogle Scholar
• HUBER TJ, DIETRICH DE, EMRICH HM: Possible use of amantadine in depression. Pharmacopsychiatry (1999) 32 (2) :47–55.
   PubMed Web of Science ®Google Scholar
• STRYJER R, STROUS RD, SHAKED G et al.: Amantadine as augmentation therapy in the management of treatment-resistant depression. Int. Clin. Psychopharmacol. (2003) 18(2):93–96.
   PubMed Web of Science ®Google Scholar
• GORTELMEYER R, ERBLER H: Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung (1992) 42 (7) :904–913.
   PubMedGoogle Scholar
• AMBROZI L, DANIELCZYK W: Treatment of impaired cerebral function in psychogeriatric patients with memantine-results of a Phase II double-blind study. Pharmacopsychiatry (1988) 21(3):144–146.
   PubMed Web of Science ®Google Scholar
• BERMAN RM, CAPPIELLO A, ANAND A et al.: Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry (2000) 47(4):351–354.
   PubMed Web of Science ®Google Scholar
• KUDOH A, TAKAHIRA Y, KATAGAI H, TAKAWA T et al.: Small-dose ketamine improves the postoperative state of depressed patients. Anesth. Analg. (2002) 95(1):114–118.
   PubMedGoogle Scholar
• STANDAERT DG, TESTA CM, YOUNG AB, PENNEY JB Jr et al: Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol (1994) 343(1):1–16.
   PubMed Web of Science ®Google Scholar
• MAREK GJ: Metabotropic glutamate 2/3 receptors as drug targets. Curr. Opin. Pharmacol (2004) 4(1):18–22.
   PubMedGoogle Scholar
• PAUL IA, SKOLNICK P: Glutamate and depression: clinical and preclinical studies. In: Glutamate, and disorders of cognition and motivation. Moghaddam B, Wolf M (Eds) (2003):252–272.
   Google Scholar
• KIM SJ, KIM YS, YUAN JP et al: Activation of the TRPC1 cation channel by metabotropic glutamate receptor mGluRl. Nature (2003) 426(6964):285–291.
   PubMedGoogle Scholar
• WHITE AM, KYLANP AR, CHRISTIE LA et al.: Presynaptic group I metabotropic glutamate receptors modulate synaptic transmission in the rat superior colliculus via 4-AP sensitive K(+) channels. BE J. Pharmacol (2003) 140 (8) :1421–1433.
   PubMed Web of Science ®Google Scholar
• MATRISCIANO F, STORTO M, NGOMBA RT et al: Imipramine treatment up-regulates the expression and function of mG1u2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology (2002) 42(8):1008–1015.
   PubMedGoogle Scholar
• GRILLON C, CORD OVA J, LEVINE LR, MORGAN CA: Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (2003) 168(4):446–454.
   PubMed Web of Science ®Google Scholar
• FEINBERG I, CAMPBELL IG, SCHOEPP DD, ANDERSON K: The selective group mG1u2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat. Pharmacol Biochem. Behav. (2002) 73(2):467–474.
   PubMedGoogle Scholar
• QUIRK JC, LINDEN AM, STRAKHOVA M et al.: A single residue contributes sensitivity to allosteric modulation of AMPA receptors by LY395153. Eur. Pharmacol (2002) 454(2-3):125–129.
   PubMedGoogle Scholar
• QUIRK JC, NISENBAUM ES: LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Reviews (2002) 8(3): 255–282.
   PubMedGoogle Scholar
• BAI F, BERGERON M, NELSON DL: Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology (2003) 44(8):1013–1021.
   PubMedGoogle Scholar
• INGVAR M, AMBRO-INGERSON J, DAVIS M et al.: Enhancement by an ampakine of memory encoding in humans. Exp. Neurol (1997) 146(2)553–559.
   Google Scholar
• LYNCH G, GRANGER R, AMBROS-INGERSON J et al: Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp. Neurol. (1997) 145 (1):89–92.
   PubMed Web of Science ®Google Scholar
• FOGELSON DL, STERNBACH H: Lamotrigine treatment of refractory bipolar disorder. J. Clin. Psychiatry (1997) 58(6):271–273.
   PubMedGoogle Scholar
• BOWDEN CL, KARREN NU: Lamotrigine in the treatment of bipolar disorder. Expert Opin. Pharmacother. (2002) 3(10):1513–1519.
   PubMedGoogle Scholar
• HURLEY SC: Lamotrigine update and its use in mood disorders. Ann. Pharmacother. (2002) 36(5):860–873.
   PubMed Web of Science ®Google Scholar
• BOWDEN CL: Novel treatments for bipolar disorder. Expert Opin. Investig. Drugs (2001) 10(4):661–671.
   PubMed Web of Science ®Google Scholar
• FRYE MA, KETTER TA, KIMBRELL TA et al: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Psychopharmacol (2000) 20(6):607–614.
   Google Scholar
• CALABRESE JR, SUPPES T, BOWDEN CL et al.: A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J. Clin. Psychiatry (2000) 61(10:841–850.
   Google Scholar
• BOWDEN CL, CALABRESE JR, SACHS G et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. an. Psychiatry (2003) 60(4):392–400.
   PubMed Web of Science ®Google Scholar
• BARBEE JG, JAMHOUR NJ: Lamotrigine as an augmentation agent in treatment-resistant depression. J. Clin. Psychiatry (2002) 63(8):737–741.
   PubMed Web of Science ®Google Scholar
• NORMANN C, HUMMEL B, SCHARER LO et al.: Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J. Chit. Psychiatry (2002) 63(4):337–344.
   PubMed Web of Science ®Google Scholar
• OBROCEA GV, DUNN RM, FRYE MA et al: Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol. Psychiatry (2002) 51 (3) : 253–260.
   PubMed Web of Science ®Google Scholar
• CORIC V, MILANOVIC S, WASYLINK S et al: Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (2003) 167(2):219–220.
   PubMedGoogle Scholar
• ZARATE CA Jr, PAYNE J, QUIROZ J et al.: Riluzole: an investigation of the antidepressant efficacy of an antiglutamateric agent with neruotrophic properties. ACNE 2002, San Juan, PR.
   Google Scholar
• MACIVER MB, AMAGASU SM, MIKULEC AA, MONROE FA: Riluzole anesthesia: use-dependent block of presynaptic glutamate fibers. Anesthesiology (1996) 85(3):626–634.
   PubMedGoogle Scholar
• GOLEMBIOWSKA K, ZYLEWSKA A: Effect of antidepressant drugs on veratridine-evoked glutamate and aspartate release in rat prefrontal cortex. Pol.j Pharmacol (1999) 51(1):63–70.
   PubMedGoogle Scholar
• MICHAEL-TITUS AT, BAINS S, JEETLE J, WHELPTON R: Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience (2000) 100(4):681–684.
   PubMed Web of Science ®Google Scholar
• POPOLI M, GENNARELLI M, RACAGNI G: Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disord. (2002) 4(3):166–82.
   PubMedGoogle Scholar
• BOURON A, CHATTON JY: Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus. Neuroscience (1999) 90(3):729–36.
   PubMedGoogle Scholar
• DIXON JF, HOKIN LE: Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc. Nati Acad. Li. USA (1998) 95(14)8363–8368.
   Google Scholar
• WINGROVE PB, SAFO P, WHEAT L et al.: Mechanism of alpha-subunit selectivity of benzodiazepine pharmacology at gamma-aminobutyric acid type A receptors. Eur. Pharinacol. (2002) 437(1-2):31–39.
   PubMedGoogle Scholar
• HEVERS W, LUDDENS H: The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol Neurobiol. (1998) 18(1):35–86.
   Google Scholar
• REYNOLDS IJ, MILLER RJ: Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. BE J. Pharinacol (1988) 95(1):95–102.
   Google Scholar
• MAJ J, ROGOZ Z, SKUZA G, SOWINSKA H: Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur. Neuropsychopharinacol (1992) 2(1):37–41.
   PubMedGoogle Scholar
• PAPP M, MORYL E: Rewarding properties of non-competitive and competitive NMDA antagonists as measured by place preference conditioning in rats. PoI.j Pharinacol (1994) 46(1-2):79–81.
   PubMedGoogle Scholar
• OSSOWSKA G, KLENK-MAJEWSKA B, SZYMCZYK G: The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats../. Physic]. Phannacol (1997) 48(1):127–135.
   Google Scholar
• ROGOZ Z, SKUZA G, MAJ J, DANYSZ W: Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharinacology (2002) 42(8):1024–1030.
   PubMedGoogle Scholar
• TRULLAS R, SKOLNICK P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. Pharinacol. (1990) 185(1):1–10.
   PubMed Web of Science ®Google Scholar
• PADOVAN CM, DEL BEL EA, GUIMARAES FS: Behavioral effects in the elevated plus maze of an NMDA antagonist injected into the dorsal hippocampus: influence of restraint stress. Phannacol Biochein. Behav. (2000) 67(2):325–330.
   PubMedGoogle Scholar
• PAPP M, MORYL E: Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur. Phannacol (1996) 316(2-3):145–151.
   PubMedGoogle Scholar